Downregulation of the expression of HDGF attenuates malignant biological behaviors of hilar cholangiocarcinoma cells

Liu,Yanfeng; Sun,Jingxian; Yang,Guangyun; Liu,Zhaojian; Guo,Sen; Zhao,Rui; Xu,Kesen; Wu,Xiaopeng; Zhang,Zhaoyang

doi:10.3892/mmr.2015.3922

Downregulation of the expression of HDGF attenuates malignant biological behaviors of hilar cholangiocarcinoma cells

Authors:
- Yanfeng Liu
- Jingxian Sun
- Guangyun Yang
- Zhaojian Liu
- Sen Guo
- Rui Zhao
- Kesen Xu
- Xiaopeng Wu
- Zhaoyang Zhang
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250011, P.R. China, Department of Hepatobiliary Surgery, The General Hospital of PLA, Beijing 100853, P.R. China, Institute of Cell Biology, Shandong University School of Medicine, Jinan, Shandong 250012, P.R. China, Department of Emergency Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: June 12, 2015 https://doi.org/10.3892/mmr.2015.3922
Pages: 4713-4719

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatoma-derived growth factor (HDGF) has been reported to be a potential predictive and prognostic marker for several types of cancer and important in malignant biological behaviors. However, its role in human hilar cholangiocarcinoma remains to be elucidated. Our previous study demonstrated that high expression levels of HDGF in hilar cholangiocarcinoma tissues correlates with tumor progression and patient outcome. The present study aimed to elucidate the detailed functions of the HDGF protein. This was performed by downregulating the protein expression of HDGF in the FRH0201 hilar cholangiocarcinoma cell line by RNA interference (RNAi) in vitro, and revealed that downregulation of the HDGF protein significantly inhibited the malignant biological behavior of the FRH0201 cells. In addition, further investigation revealed that downregulation of the protein expression of HDGF significantly decreased the secretion of vascular endothelial growth factor, which may be the mechanism partially responsible for the inhibition of malignant biological behaviors. These findings demonstrated that HDGF is important in promoting malignant biological behaviors, including proliferation, migration and invasion of hilar cholangiocarcinoma FRH0201 cells. Inhibition of the expression of HDGF downregulated the malignant biological behaviors, suggesting that downregulation of the protein expression of HDGF by RNAi may be a novel therapeutic approach to inhibit the progression of hilar cholangiocarcinoma.

View Figures

View References

1	Khans A, Thomas HC, Davidson BR and Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 366:1303–1314. 2005. View Article : Google Scholar
2	Ortner MA and Dorta G: Technology insight: Photodynamic therapy for cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 3:459–467. 2006. View Article : Google Scholar : PubMed/NCBI
3	Zhang BY, Lu Y, Dong Q, Sun CD and Mu P: Surgical treatment and prognostic analysis of 93 cases of hilar cholangiocarcinoma. Am J Med Sci. 339:221–224. 2010. View Article : Google Scholar : PubMed/NCBI
4	Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BS J, Youssef BA M, Klimstra D and Blumgart LH: Staging, resectability and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 234:507–517; discussion 517–519. 2001. View Article : Google Scholar
5	Patel T: Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 3:33–42. 2006. View Article : Google Scholar : PubMed/NCBI
6	Jarnagin WR and Shoup M: Surgical management of cholangiocarcinoma. Semin Liver Dis. 24:189–199. 2004. View Article : Google Scholar : PubMed/NCBI
7	Nakamura H, Izumoto Y, Kambe H, Kuroda T, Mori T, Kawamura K, Yamamoto H and Kishimoto T: Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem. 269:25143–25149. 1994.PubMed/NCBI
8	Nakamura H, Kambe H, Egawa T, Kimura Y, Ito H, Hayashi E, Yamamoto H, Sato J and Kishimotos: Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta. 183:273–284. 1989. View Article : Google Scholar : PubMed/NCBI
9	Okuda Y, Nakamura H, Yoshida K, Enomoto H, Uyama H, Hirotani T, Funamoto M, Ito H, Everett AD, Hada T, et al: Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci. 94:1034–1041. 2003. View Article : Google Scholar : PubMed/NCBI
10	Zhang J, Ren H, Yuan P, Lang W, Zhang L and Mao L: Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res. 66:18–23. 2006. View Article : Google Scholar : PubMed/NCBI
11	Everett AD, Narron JV, Stoops T, Nakamura H and Tucker A: Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol. 286:L1194–L1201. 2004. View Article : Google Scholar : PubMed/NCBI
12	Guo Z, He Y, Wang S, Zhang A, Zhao P, Gao C and Cao B: Various effects of hepatoma-derived growth factor on cell growth, migration and invasion of breast cancer and prostate cancer cells. Oncol Rep. 26:511–517. 2011.PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
14	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
15	Everett AD and Bushweller J: Hepatoma derived growth factor is a nuclear targeted mitogen. Curr Drug Targets. 4:367–371. 2003. View Article : Google Scholar : PubMed/NCBI
16	Everett AD, Stoops T and McNamara CA: Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem. 276:37564–37568. 2001. View Article : Google Scholar : PubMed/NCBI
17	Kishima Y, Yamamoto H, Izumoto Y, Yoshida K, Enomoto H, Yamamoto M, Kuroda T, Ito H, Yoshizaki K and Nakamura H: Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem. 277:10315–10322. 2002. View Article : Google Scholar
18	Zhou Z, Yamamoto Y, Sugai F, Yoshida K, Kishima Y, Sumi H, Nakamura H and Sakodas: Hepatoma-derived growth factor is a neurotrophic factor harbored in the nucleus. J Biol Chem. 279:27320–27326. 2004. View Article : Google Scholar : PubMed/NCBI
19	Everett AD, Lobe DR, Matsumura ME, Nakamura H and McNamara CA: Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest. 105:567–575. 2000. View Article : Google Scholar : PubMed/NCBI
20	Ooi BN, Mukhopadhyay A, Masilamani J, Do DV, Lim CP, Cao XM, Lim IJ, Mao L, Ren HN, Nakamura H, et al: Hepatoma-derived growth factor and its role in keloid pathogenesis. J Cell Mol Med. 14:1328–1337. 2010. View Article : Google Scholar
21	Meng J, Xie W, Cao L, Hu C and Zhe Z: shRNA targeting HDGF suppressed cell growth and invasion of squamous cell lung cancer. Acta Biochim Biophys Sin (Shanghai). 42:52–57. 2010. View Article : Google Scholar
22	Tsang TY, Tang WY, Tsang WP, Co NN, Kongs K and Kwok TT: Mechanistic study on growth suppression and apoptosis induction by targeting hepatoma-derived growth factor in human hepatocellular carcinoma HepG2 cells. Cell Physiol Biochem. 24:253–262. 2009. View Article : Google Scholar : PubMed/NCBI
23	Yu Y, Shen H, Yu H, Zhong F, Zhang Y, Zhang C, Zhao J, Li H, Chen J, Liu Y, et al: Systematic proteomic analysis of human hepotacellular carcinoma cells reveals molecular pathways and networks involved in metastasis. Mol Biosyst. 7:1908–1916. 2011. View Article : Google Scholar : PubMed/NCBI
24	Carson DA and Ribeiro JM: Apoptosis and disease. Lancet. 341:1251–1254. 1993. View Article : Google Scholar : PubMed/NCBI
25	Tsang TY, Tang WY, Tsang WP, Co NN, Kongs K and Kwok TT: Downregulation of hepatoma-derived growth factor activates the Bad-mediated apoptotic pathway in human cancer cells. Apoptosis. 13:1135–1147. 2008. View Article : Google Scholar : PubMed/NCBI
26	Ren H, Chu Z and Mao L: Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther. 8:1106–1112. 2009. View Article : Google Scholar : PubMed/NCBI
27	Liao F, Dong W and Fan L: Apoptosis of human colorectal carcinoma cells is induced by blocking hepatoma-derived growth factor. Med Oncol. 27:1219–1226. 2010. View Article : Google Scholar
28	Sahai E: Mechanisms of cancer cell invasion. Curr Opin Genet Dev. 15:87–96. 2005. View Article : Google Scholar : PubMed/NCBI
29	Valastyans and Weinberg RA: Tumor metastasis: Molecular insights and evolving paradigms. Cell. 147:275–292. 2011. View Article : Google Scholar
30	Zhou Y, Zhou N, Fang W and Huo J: Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer. Diagn Pathol. 5:582010. View Article : Google Scholar : PubMed/NCBI
31	Liu YF, Zhao R, Guo S, Wang XQ, Lian PL, Chen YG and Xu KS: Expression and clinical significance of hepatoma-derived growth factor as a prognostic factor in human hilar cholangio-carcinoma. Ann Surg Oncol. 18:872–879. 2011. View Article : Google Scholar
32	Maeda K, Chung YS, Takatsukas, Ogawa Y, Sawada T, Yamashita Y, Onoda N, Kato Y, Nitta A, Arimoto Y, et al: Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol. 13:477–481. 1995.PubMed/NCBI
33	Oliver JA and Al-Awqati Q: An endothelial growth factor involved in rat renal development. J Clin Invest. 102:1208–1219. 1998. View Article : Google Scholar : PubMed/NCBI
34	Mao J, Xu Z, Fang Y, Wang H, Xu J, Ye J, Zhengs and Zhu Y: Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci. 99:2120–2127. 2008. View Article : Google Scholar : PubMed/NCBI
35	Lee KH, Choi EY, Kim MK, Lee SH, Jang BI, Kim TN, Kims W, Kims W, Songs K, Kim JR, et al: Hepatoma-derived growth factor regulates the bad-mediated apoptotic pathway and induction of vascular endothelial growth factor in stomach cancer cells. Oncol Res. 19:67–76. 2010. View Article : Google Scholar
36	Ooi BN, Mukhopadhyay A, Masilamani J, Do DV, Lim CP, Cao XM, Lim IJ, Mao L, Ren HN, Nakamura H, et al: Hepatoma-derived growth factor and its role in keloid pathogenesis. J Cell Mol Med. 14:1328–1337. 2010. View Article : Google Scholar
37	Okuda Y, Nakamura H, Yoshida K, Enomoto H, Uyama H, Hirotani T, Funamoto M, Ito H, Everett AD, Hada T, et al: Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci. 94:1034–1041. 2003. View Article : Google Scholar : PubMed/NCBI